{"log_id": 1982999485053089808, "direction": 0, "words_result_num": 48, "words_result": [{"probability": {"variance": 0.000659, "average": 0.992684, "min": 0.831647}, "location": {"width": 891, "top": 207, "height": 50, "left": 202}, "words": "过血液透析清除阿德福韦,阿德福韦经体重校正后的血液透析清除率中位数为104ml/min。尚未"}, {"probability": {"variance": 0.000241, "average": 0.993448, "min": 0.946581}, "location": {"width": 323, "top": 254, "height": 35, "left": 202}, "words": "进行腹膜透析清除阿德福韦的研究"}, {"probability": {"variance": 0, "average": 0.999524, "min": 0.998452}, "location": {"width": 116, "top": 293, "height": 27, "left": 213}, "words": "【药理毒理】"}, {"probability": {"variance": 8e-06, "average": 0.997959, "min": 0.988413}, "location": {"width": 850, "top": 305, "height": 50, "left": 247}, "words": "作用机制:本品阿德福韦酯是一种口服抗病毒药。阿德福韦酯在体内代谢成阿德福韦,阿德"}, {"probability": {"variance": 1e-06, "average": 0.99892, "min": 0.99532}, "location": {"width": 895, "top": 338, "height": 51, "left": 204}, "words": "福韦是一种单磷酸腺苷的无环核苷类似物,在细胞激酶的作用下进一步被磷酸化为有活性的代谢"}, {"probability": {"variance": 0.000533, "average": 0.993725, "min": 0.856381}, "location": {"width": 891, "top": 370, "height": 53, "left": 205}, "words": "产物即阿德福韦二磷酸盐。阿德福韦二磷酸盐通过下列两种方式来抑制 HBV DNA多聚酶(逆转"}, {"probability": {"variance": 0.0001, "average": 0.993646, "min": 0.956467}, "location": {"width": 870, "top": 403, "height": 53, "left": 205}, "words": "录酶):一是与自然底物脱氧腺苷三磷酸竞争,二是整合到病毒DNA后引起DNA链延长终止"}, {"probability": {"variance": 7.4e-05, "average": 0.995022, "min": 0.963319}, "location": {"width": 897, "top": 437, "height": 50, "left": 202}, "words": "阿德福韦二磷酸盐对 HBV DNA多聚酶的抑制常数(Ki)是0.1μM,但对人类DNA多聚酶a和"}, {"probability": {"variance": 0.000482, "average": 0.986472, "min": 0.907619}, "location": {"width": 499, "top": 480, "height": 40, "left": 207}, "words": "Y的抑制作用较弱,Ki值分别为1.18μM和0.97μM"}, {"probability": {"variance": 0.005457, "average": 0.982892, "min": 0.495815}, "location": {"width": 846, "top": 503, "height": 49, "left": 248}, "words": "抗病毒活性:在转染HBV的人肝瘤细胞系中,阿德福韦抑制50%病毒DNA复制的浓度(IC50"}, {"probability": {"variance": 0.013032, "average": 0.938667, "min": 0.706466}, "location": {"width": 142, "top": 558, "height": 25, "left": 207}, "words": "为0.2~2.5μM"}, {"probability": {"variance": 6.3e-05, "average": 0.996739, "min": 0.951928}, "location": {"width": 852, "top": 568, "height": 49, "left": 247}, "words": "耐药性:对接受阿德福韦酯治疗仍然可检测到血清 HBV DNA的患者进行了长期耐药性分析"}, {"probability": {"variance": 0.009591, "average": 0.96142, "min": 0.408545}, "location": {"width": 893, "top": 599, "height": 53, "left": 208}, "words": "96~144周),确定了rtN236T和IrA18V变异与阿德福韦耐药有关。体外研究发现rtN236T变异"}, {"probability": {"variance": 0.003852, "average": 0.98726, "min": 0.594475}, "location": {"width": 894, "top": 634, "height": 49, "left": 207}, "words": "导致HBV对阿德福韦的敏感性降低4~14倍,产生这种变异的6/6名患者的血清 HBV DNA发生"}, {"probability": {"variance": 0.011764, "average": 0.96007, "min": 0.478099}, "location": {"width": 895, "top": 666, "height": 51, "left": 207}, "words": "反跳。rtAl81V变异导致HBV对阿德福韦的敏感性降低2.5~3倍,产生这种变异的23名患者发"}, {"probability": {"variance": 0.008756, "average": 0.97218, "min": 0.417899}, "location": {"width": 892, "top": 700, "height": 49, "left": 207}, "words": "生反跳。与阿德福韦耐药相关的变异发生率0~48周为0%(0629),49~96周为2%(6293),97~"}, {"probability": {"variance": 0.004283, "average": 0.968716, "min": 0.737839}, "location": {"width": 447, "top": 742, "height": 40, "left": 219}, "words": "44周为1.8%(3/163),3年的累计发生率为3.9"}, {"probability": {"variance": 0.004367, "average": 0.971927, "min": 0.645946}, "location": {"width": 804, "top": 764, "height": 49, "left": 251}, "words": "交叉耐药性:在 HBV DNA多聚酶基因上含对拉米夫定耐药相关突变(rtL180M,rtM2"}, {"probability": {"variance": 0.007905, "average": 0.952093, "min": 0.525983}, "location": {"width": 896, "top": 795, "height": 53, "left": 208}, "words": "tM204V,rtL180M+rtM204V,rtV173L)的重组HBV变异株,在体外对阿德福韦敏感。在含拉米"}, {"probability": {"variance": 0.002101, "average": 0.987867, "min": 0.713745}, "location": {"width": 897, "top": 828, "height": 51, "left": 208}, "words": "大定耐药相关变异HBV的患者中,阿德福韦酯也显示了抗HBV作用,其血清 HBVDNA下降的"}, {"probability": {"variance": 0.015513, "average": 0.928549, "min": 0.550499}, "location": {"width": 896, "top": 860, "height": 53, "left": 209}, "words": "中位数为4.3log10拷贝数/毫升。含DNA多聚酶突变(rT128N和rtR153Q或rtW153Q,与乙型肝炎"}, {"probability": {"variance": 0.000415, "average": 0.992684, "min": 0.868984}, "location": {"width": 895, "top": 892, "height": 53, "left": 211}, "words": "免疫球蛋白耐药相关)的HBV变异株,在体外对阿德福韦敏感。体外研究显示,表达与阿德福韦"}, {"probability": {"variance": 0.005272, "average": 0.981164, "min": 0.597849}, "location": {"width": 897, "top": 926, "height": 51, "left": 209}, "words": "耐药相关的rtN236T突变的HBV对拉米大定的敏感性降低2~3倍,而与阿德福韦耐药相关的"}, {"probability": {"variance": 0.01067, "average": 0.953977, "min": 0.586411}, "location": {"width": 480, "top": 968, "height": 43, "left": 210}, "words": "tAl81V突变的HBV对拉米夫定的敏感性降低3倍"}, {"probability": {"variance": 0.052358, "average": 0.817096, "min": 0.355534}, "location": {"width": 290, "top": 979, "height": 43, "left": 781}, "words": "受理号C HB Po02"}, {"probability": {"variance": 3e-06, "average": 0.997973, "min": 0.99571}, "location": {"width": 87, "top": 1013, "height": 25, "left": 254}, "words": "毒理研究"}, {"probability": {"variance": 0.003881, "average": 0.975835, "min": 0.672233}, "location": {"width": 837, "top": 1020, "height": 57, "left": 253}, "words": "慢性毒性:在动物试验中,以组织学改变和/或尿素氮血清肌酐升高为特征的肾小管肾病"}, {"probability": {"variance": 0.00294, "average": 0.987357, "min": 0.686813}, "location": {"width": 714, "top": 1059, "height": 50, "left": 212}, "words": "是阿德福韦酯的主要剂量限制性毒性反应。在动物试验中观到的肾毒性发"}, {"probability": {"variance": 0.0426, "average": 0.852282, "min": 0.523299}, "location": {"width": 124, "top": 1052, "height": 32, "left": 984}, "words": "露量缔为推荐"}, {"probability": {"variance": 0.008133, "average": 0.955095, "min": 0.624706}, "location": {"width": 329, "top": 1105, "height": 36, "left": 215}, "words": "的人治疗量(10mg/天)下的3~10倍"}, {"probability": {"variance": 7e-06, "average": 0.997973, "min": 0.990315}, "location": {"width": 514, "top": 1127, "height": 47, "left": 255}, "words": "遗传毒性:在体外小鼠淋巴细胞瘤试验中(有或无代谢"}, {"probability": {"variance": 0.039029, "average": 0.868121, "min": 0.454192}, "location": {"width": 391, "top": 1103, "height": 49, "left": 779}, "words": "收到备案资料法号执行"}, {"probability": {"variance": 0.001627, "average": 0.983651, "min": 0.841573}, "location": {"width": 899, "top": 1150, "height": 58, "left": 213}, "words": "人外周血淋巴细胞试验中,无代谢活化时,阿德福韦酯能诱导染色体崎变。阿德福韦酯微核"}, {"probability": {"variance": 0.001637, "average": 0.987709, "min": 0.788577}, "location": {"width": 712, "top": 1188, "height": 52, "left": 215}, "words": "试验结果为阴性,阿德福韦在有或无代谢活化时Ames试验结果为阴注"}, {"probability": {"variance": 0.011886, "average": 0.957311, "min": 0.392825}, "location": {"width": 859, "top": 1207, "height": 69, "left": 257}, "words": "生殖毒性:当暴露量大约为人治疗剂量下暴露量的19倍时,未见对大鼠生力的影大鼠"}, {"probability": {"variance": 0.007526, "average": 0.964573, "min": 0.524259}, "location": {"width": 900, "top": 1248, "height": 58, "left": 214}, "words": "经口给予阿德福韦酯(暴露量分别约为人治疗剂量10mg天下的23和40倍胚胎毒和致畸"}, {"probability": {"variance": 0.002515, "average": 0.983922, "min": 0.697522}, "location": {"width": 899, "top": 1280, "height": 59, "left": 215}, "words": "作用。妊娠大鼠静脉注射给予阿德福韦,在能产生明显母体毒性的剂量时(相当子人体暴露量的"}, {"probability": {"variance": 0.013605, "average": 0.965755, "min": 0.416771}, "location": {"width": 894, "top": 1316, "height": 53, "left": 220}, "words": "38倍),胚胎毒性和胎仔畸形(全身性水肿,眼泡凹陷,脐疝和尾巴扭结)的发生率增加在静脉注"}, {"probability": {"variance": 3.8e-05, "average": 0.996637, "min": 0.980824}, "location": {"width": 426, "top": 1360, "height": 43, "left": 216}, "words": "射剂量相等于人暴露量12倍时未见不良影响"}, {"probability": {"variance": 2.5e-05, "average": 0.997921, "min": 0.967963}, "location": {"width": 839, "top": 1382, "height": 52, "left": 258}, "words": "致癌性:小鼠和大鼠经口给予阿德福韦酯,剂量分别相当于人治疗剂量时暴露量的10倍和"}, {"probability": {"variance": 3e-06, "average": 0.998488, "min": 0.994423}, "location": {"width": 198, "top": 1435, "height": 33, "left": 218}, "words": "倍时,未见致癌作用"}, {"probability": {"variance": 0, "average": 0.83874, "min": 0.83874}, "location": {"width": 139, "top": 1439, "height": 34, "left": 1001}, "words": "七"}, {"probability": {"variance": 0, "average": 0.999384, "min": 0.998729}, "location": {"width": 141, "top": 1468, "height": 34, "left": 224}, "words": "【药代动力学】"}, {"probability": {"variance": 0.01443, "average": 0.965654, "min": 0.392906}, "location": {"width": 898, "top": 1478, "height": 56, "left": 261}, "words": "据国外文献报道:阿德福韦酯是活性成份阿德福韦的前体药物。口服给药后,阿德福韦酯迅"}, {"probability": {"variance": 0.00564, "average": 0.977388, "min": 0.604679}, "location": {"width": 954, "top": 1498, "height": 74, "left": 217}, "words": "速地转化为阿德福韦。健康志愿者与慢性乙肝病人服用阿德福韦酯的药代动力学相似。服阿德"}, {"probability": {"variance": 0.008042, "average": 0.970547, "min": 0.568773}, "location": {"width": 939, "top": 1547, "height": 54, "left": 220}, "words": "福韦酯10mg阿德福韦的生物利用度为59%。慢性乙型肝炎患者单剂口服本品10mg后达到药年"}, {"probability": {"variance": 0.007192, "average": 0.966495, "min": 0.560364}, "location": {"width": 935, "top": 1563, "height": 72, "left": 222}, "words": "峰浓度(Cma)的中位数时间为1.75小时(范围:0.58~4.0小时)。Cmax的中位数为16.70(966"}, {"probability": {"variance": 0.003538, "average": 0.973961, "min": 0.584395}, "location": {"width": 895, "top": 1614, "height": 54, "left": 224}, "words": "0.56)ng/ml,AUC的中位数为204.40(109.75~356.05)ng·h/ml。血浆阿德福韦以二房室方式"}], "language": 3}